Kindeva Appoints David Stevens as CCO

Kindeva Drug Delivery, a contract development and manufacturing organization (CDMO) focused on drug-device combination products, has appointed David Stevens as its new chief commercial officer (CCO).
 
Stevens will lead the commercial, business development, and research and development activities for the business.
 
“David brings a breadth of industry experience and a depth of commercial expertise that is essential for driving Kindeva’s enhanced scope and scale,” Kindeva CEO Milton Boyer told the press. “His role is vital to our continued success as a premier CDMO and, in turn, the success of our partners bringing a broad range of drug delivery solutions to market.”
 
Stevens has over 20 years of international operations and commercial experience in both the CDMO and contract research organization (CRO) sectors. Before Kindeva, Stevens was CEO of advanced therapy CDMO Arranta Bio (acquired by Recipharm in 2022). He had multiple roles at AMRI before that and throughout his tenure had positions at Aptuit, Inveresk, and Charles River Laboratories.
 
“The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said. “I am excited to work with the incredible experts bringing many life-changing therapies and the highest-quality products to patients, and I am looking forward to leveraging my commercial, operational, and strategic background to enable continued success for our partners worldwide.”